Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Interventionsstudie
Phase 2
West China Hospital of Sichuan University
Sponsor: Zelgen Biopharmaceuticals
Zuletzt aktualisiert: 25. März 2025 Hinweis - Die Informationen stammen aus öffentlichen Registern und spiegeln möglicherweise nicht die Echtzeitänderungen am lokalen Studienzentrum wider.
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Behandlungskategorie
Andere Medikamente, Monoklonaler Antikörper, Checkpoint-Inhibitoren